ClinicalTrials.gg
TerminatedNCT00734435Updated Nov 29, 2012

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

A Phase 2 interventional study of zonisamide SR plus olanzapine and Placebo plus olanzapine in Schizophrenia, Schizoaffective Disorder and Schizophreniform Disorder, sponsored by Orexigen Therapeutics, Inc. Terminated at 9 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-11-29.

Sponsored by Orexigen Therapeutics, Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision- Financial Considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
80th of 94
26 · median 114
Started
2008
with 5 others
Phase 2
5 of 97
none open now
Registered
57th of 97
by date

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 80th largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2008, is one of 5 in phase 2, and was the 57th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorder

Keywords

  • schizophrenia
  • schizophreniform
  • schizoaffective disorder
  • Zyprexa
  • olanzapine
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects,18-55 years of age
  • Outpatients diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder
  • (BMI) between 22-35 kg/m2 (inclusive)
  • Negative serum pregnancy test in women of
  • If women of child-bearing potential, must be non-lactating and agree to use an acceptable form of , which in all cases, includes one type of barrier method, throughout the study period and for 30 days after discontinuation of study drug
  • Subject requires a change in antipsychotic treatment and olanzapine is deemed by the Investigator to be a reasonable antipsychotic treatment choice
  • No abnormality on
  • No clinically significant laboratory abnormality
  • Negative urine drug screen
  • Must be considered reliable and possess a level of understanding that enables the subject to provide written and to comply with protocol procedures and schedule
  • Must be able to read and understand English

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of substance dependence within the 6 months prior to randomization
  • diagnosis of substance abuse (except for nicotine and caffeine) within the 3 months prior to randomization
  • Suicidal behavior or ideation within 3 months prior to randomization, or any current suicidal ideation or intent
  • Presence of dementia or other organic brain syndrome
  • Serious or unstable medical illnesses
  • Known, uncorrected narrow-angle glaucoma
  • Diagnosis of eating disorder as defined by within 6 months prior to randomization
  • Require treatment with any typical or atypical antipsychotic in addition to olanzapine
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    1

    Zonisamide SR 360 mg and olanzapine 10-20 mg daily

    Drug: zonisamide SR plus olanzapine

  • Placebo comparator
    2

    Placebo and olanzapine 10-20 mg daily

    Drug: Placebo plus olanzapine

Interventions

  • Drugzonisamide SR plus olanzapine

    Drug pages: Zonisamide · Olanzapine

    zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)

    Also known as: Zyprexa

  • DrugPlacebo plus olanzapine

    Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)

    Also known as: Zyprexa

06

What researchers measure

Primary outcomes

  1. Percentage change in total body weight

    Time frame: Baseline to Week 16

07

Study locations

9 sites
  • Synergy Research
    National City, California 91950, United States
  • UCI Medical Center
    Orange, California 92868, United States
  • CNRI San Diego
    San Diego, California 92126, United States
  • Florida Clincal Research Center
    Bradenton, Florida 34208, United States
  • Florida Clinical Research Center
    Maitland, Florida 34208, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • American Medical Research
    Oak Brook, Illinois 60523, United States
  • Larue D. Carter Hospital
    Indianapolis, Indiana 46222, United States
  • Brooklyn Medical Institute
    Brooklyn, New York 11223, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2008
First posted
Aug 14, 2008
Start
Sep 2008
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results delay requested
Nov 27, 2012
Last update
Nov 29, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00734435
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
Aug 14, 2008
Start date
Sep 2008
Primary completion
Dec 2008
Completion
Dec 2008
Last update
Nov 29, 2012

Study contacts

Alan Breier, MD
principal investigator · Larue D. Carter Hospital
Mohammed Alam, MD
principal investigator · American Medical Research
Gerald Maguire, MD
principal investigator · UCI Medical Center
Zinoviy Benzar, MD
principal investigator · Brooklyn Medical Institute
Mohammed Bari, MD
principal investigator · Synergy Research
Tran Johnson, MD
principal investigator · CNRI
Eduard Gfeller, MD
principal investigator · Florida Clinical Research Center, Maitland Florida
Andrew Cutler, MD
principal investigator · Florida Clinical Research Center, Bradenton Florida
Robert Riesenberg, MD
principal investigator · Atlanta Center for Medical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zonisamide · Olanzapine

Start the discussion